Effects of YM471, a nonpeptide AVP V1A and V2 receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells

British Journal of Pharmacology

Volumn 133, Issue 5, 2001, Pages 746-754

  Tsukada, J ^a   Tahara, A ^a   Tomura, Y ^a   Wada, K I ^a   Kusayama, T ^a   Ishii, N ^a   Yatsu, T ^a   Uchida, W ^a   Taniguchi, N ^a   Tanaka, A ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Antagonist; Human vasopressin receptors; SR 121463A; SR 49059; YM471

Indexed keywords

4' [4,4 DIFLUORO 5 [2 (4 DIMETHYLAMINOPIPERIDINO) 2 OXOETHYLIDENE] 2,3,4,5 TETRAHYDRO 1H 1 BENZOAZEPINE 1 CARBONYL] 2 PHENYLBENZANILIDE; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; OXYTOCIN RECEPTOR; RELCOVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; YM 471;

ANIMAL CELL; ARTICLE; CHO CELL; DRUG EFFECT; DRUG POTENCY; HAMSTER; HORMONE RELEASE; HUMAN; HUMAN CELL; LIGAND BINDING; MYOMETRIUM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SECOND MESSENGER; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

EID: 0034934526     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704117     Document Type: Article

References (46)

1. Treatment of hyponatremia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist
2. 2 vasopressin antagonist YM087
3. Molecular cloning of the receptor for human antidiuretic hormone
4. Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions
5. 50) of an enzymatic reaction
6. Improvement by a non-peptide vasopressin antagonist OPC-31260 of water retention in experimental rats with myocardial infarction
7. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats
8. 2+ indicators with greatly improved fluorescence properties
9. Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla: Relation of adenylate cyclase activation
10. i in single human myometrium smooth muscle cells
11. Characterization of the human liver vasopressin receptor
12. 1 renal epithelial cells at physiological temperature
13. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis
14. Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells
15. Pharmacology and clinical perspectives of vasopressin antagonists
16. 2 receptors: Synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4′-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanili de derivatives
17. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin
18. pEF-BOS, a powerful mammalian expression vector
19. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
20. Arginine vasopressin stimulates phosphorylation of aquaporin-2 in rat renal tissue
21. Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
22. Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues
23. The attraction of proteins for small molecules and ions
24. 1a antagonist, on human vascular smooth muscle cells
25. 2 receptor antagonist
26. 1a receptors
27. Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors: Synthesis and pharmacological properties of 4′-(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin- 1-yl)-carbonyl)-2-phenylbenzanilide derivatives
28. 1b vasopressin receptor
29. 2 vasopressin antagonist YM087
30. 2 receptor antagonist
31. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells
32. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells
33. 2 receptor antagonist, in vitro and in vivo
34. Characterization of vasopressin receptor in rat lung
35. Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells
36. Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells
37. A rapid filtration assay for cAMP
38. Direct measurement of intracellular free calcium in cultured human puerperal myometrial cells stimulated by oxytocin: Effects of extracellular calcium and calcium channel blockers
39. Signal transduction of V1-vascular vasopressin receptors
40. 1A, vasopressin receptor
41. Hemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1a and V2 receptor antagonist in patients with advanced heart failure
42. 2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats
43. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist
44. 2 receptor antagonist
45. Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements
46. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure